Literature DB >> 28791816

IL-6, IL-8 and TNF-α levels correlate with disease stage in breast cancer patients.

Yunfeng Ma1, Yi Ren2, Zhi-Jun Dai3, Cai-Jun Wu1, Yan-Hong Ji1, Jiru Xu1.   

Abstract

BACKGROUND: Breast cancer is the most common cancer in Chinese women. Inflammation contributes to tumor progression and can be induced by excessive production of pro-inflammatory cytokines such as interleukin-6 (IL-6), interleukin-8 (IL-8) and tumor necrosis factor-α (TNF-α). However, how their levels relate to the expression of estrogen receptors (ER), progesterone receptors (PR) and human epidermal growth factor receptor 2 (HER2) by the tumor has not been investigated.
OBJECTIVES: The aim of the study is to more fully understand the significance of serum IL-6, IL-8 and TNF-α in breast cancers with different ER, PR and HER2 status.
MATERIAL AND METHODS: Preoperative serum samples were collected from 110 patients diagnosed with ductal carcinoma and 30 healthy control subjects. IL-6, IL-8 and TNF-α levels were determined by enzyme-linked immunosorbent assay (ELISA). Associations of cytokine levels with clinical tumor stage were evaluated, and correlations of serum cytokine levels with ER, PR and HER2 expression were determined using the Pearson correlation coefficient.
RESULTS: Serum levels of IL-6 and IL-8 were significantly higher in the subjects with ductal carcinoma than in the controls, and strongly correlated with clinical tumor stage, lymph node metastasis, and ER and HER2 antigen expression (p < 0.05). TNF-α levels in stage III carcinoma patients were significantly higher than in the controls (p < 0.01) and were associated with lymph node metastasis (p < 0.01). A strong positive correlation was found between IL-8 and TNF-α levels in the cancer patients (p < 0.0001).
CONCLUSIONS: The study showed that IL-6, IL-8 and TNF-α levels correlated with clinical disease stage and lymph node metastasis as well as with ER and HER2 antigen expression. Specifically, IL-6 and IL-8 seem to have significant potential as prognostic cancer biomarkers. Analyzing serum cytokine levels might help identify patients with a poor prognosis who may benefit from more aggressive disease management.

Entities:  

Keywords:  TNF-α; biomarkers; breast cancer; interleukin-6; interleukin-8

Mesh:

Substances:

Year:  2017        PMID: 28791816     DOI: 10.17219/acem/62120

Source DB:  PubMed          Journal:  Adv Clin Exp Med        ISSN: 1899-5276            Impact factor:   1.727


  70 in total

Review 1.  Dietary fat and obesity as modulators of breast cancer risk: Focus on DNA methylation.

Authors:  Micah G Donovan; Spencer N Wren; Mikia Cenker; Ornella I Selmin; Donato F Romagnolo
Journal:  Br J Pharmacol       Date:  2020-01-26       Impact factor: 8.739

2.  Inflammatory cytokines, appetite-regulating hormones, and energy metabolism in patients with gastrointestinal cancer.

Authors:  Ayaka Shinsyu; Shigeki Bamba; Mika Kurihara; Hiroshi Matsumoto; Ayano Sonoda; Osamu Inatomi; Akira Andoh; Katsushi Takebayashi; Masatsugu Kojima; Hiroya Iida; Masaji Tani; Masaya Sasaki
Journal:  Oncol Lett       Date:  2020-05-21       Impact factor: 2.967

3.  The stimulatory effect of fusobacteria on dendritic cells under aerobic or anaerobic conditions.

Authors:  Shigeo Koido; Sankichi Horiuchi; Shin Kan; Tsuuse Bito; Zensho Ito; Kan Uchiyama; Masayuki Saruta; Nobuhiro Sato; Toshifumi Ohkusa
Journal:  Sci Rep       Date:  2022-06-23       Impact factor: 4.996

4.  STING agonist enhances the efficacy of programmed death-ligand 1 monoclonal antibody in breast cancer immunotherapy by activating the interferon-β signalling pathway.

Authors:  Mingming Yin; Jinlong Hu; Zhongxu Yuan; Guangyi Luo; Jiaming Yao; Rundong Wang; Dongquan Liu; Baoqiang Cao; Wenyong Wu; Zhiqi Hu
Journal:  Cell Cycle       Date:  2022-02-07       Impact factor: 5.173

Review 5.  Role of the parasympathetic nervous system in cancer initiation and progression.

Authors:  M Tibensky; B Mravec
Journal:  Clin Transl Oncol       Date:  2020-08-08       Impact factor: 3.405

Review 6.  The dual role of tumor necrosis factor-alpha (TNF-α) in breast cancer: molecular insights and therapeutic approaches.

Authors:  Daniel Cruceriu; Oana Baldasici; Ovidiu Balacescu; Ioana Berindan-Neagoe
Journal:  Cell Oncol (Dordr)       Date:  2020-01-03       Impact factor: 6.730

7.  TOP1 modulation during melanoma progression and in adaptative resistance to BRAF and MEK inhibitors.

Authors:  Érica Aparecida de Oliveira; Jagat Chauhan; Julia Rezende da Silva; Larissa Anastacio da Costa Carvalho; Diogo Dias; Danielle Gonçalves de Carvalho; Luis Roberto Masao Watanabe; Vito W Rebecca; Gordon Mills; Yiling Lu; Aloisio Souza Felipe da Silva; Márcia Edilaine Lopes Consolaro; Meenhard Herlyn; Patricia A Possik; Colin R Goding; Silvya Stuchi Maria-Engler
Journal:  Pharmacol Res       Date:  2021-09-22       Impact factor: 7.658

8.  MAT2A Localization and Its Independently Prognostic Relevance in Breast Cancer Patients.

Authors:  Pei-Yi Chu; Hsing-Ju Wu; Shin-Mae Wang; Po-Ming Chen; Feng-Yao Tang; En-Pei Isabel Chiang
Journal:  Int J Mol Sci       Date:  2021-05-20       Impact factor: 5.923

9.  Effects of Cancer, Chemotherapy, and Cytokines on Subjective and Objective Cognitive Functioning Among Patients with Breast Cancer.

Authors:  Vincent Chin-Hung Chen; Chin-Kuo Lin; Han-Pin Hsiao; Bor-Show Tzang; Yen-Hsuan Hsu; Shu-I Wu; Robert Stewart
Journal:  Cancers (Basel)       Date:  2021-05-24       Impact factor: 6.639

Review 10.  Crosstalk between the oral microbiota, mucosal immunity, and the epithelial barrier regulates oral mucosal disease pathogenesis.

Authors:  Dongjia Lin; Lisa Yang; Liling Wen; Huanzi Lu; Qianming Chen; Zhi Wang
Journal:  Mucosal Immunol       Date:  2021-05-26       Impact factor: 7.313

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.